MORPHINE SULFATE INJECTION USP SOLUTION

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

MORPHINE SULFATE

Disponibbli minn:

ICU MEDICAL CANADA INC

Kodiċi ATC:

N02AA01

INN (Isem Internazzjonali):

MORPHINE

Dożaġġ:

1MG

Għamla farmaċewtika:

SOLUTION

Kompożizzjoni:

MORPHINE SULFATE 1MG

Rotta amministrattiva:

INTRAVENOUS

Unitajiet fil-pakkett:

30ML

Tip ta 'preskrizzjoni:

Narcotic (CDSA I)

Żona terapewtika:

OPIATE AGONISTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0104545004; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2020-05-04

Karatteristiċi tal-prodott

_ _
_N_
_MORPHINE SULFATE INJECTION USP _
_Page 1 of 32 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
MORPHINE SULFATE INJECTION USP
Sterile Solution
1 mg/mL, 5 mg/mL
Narcotic Analgesic
ICU Medical Canada Inc.
2600, Alfred-Nobel boul., suite 100
Saint-Laurent, QC
H4S 0A9
Date of Revision:
April 4, 2018
Submission Control No: 211418
_ _
_N_
_MORPHINE SULFATE INJECTION USP _
_Page 2 of 32 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................15
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................22
SPECIAL HANDLING INSTRUCTIONS
.......................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................23
PART II: SCIENTIFIC INFORMATION
................................................................................24
PHARMACEUTICAL INFORMATION
..................................................................